Podcasts about vrd

MadMax Stambaugh dials up inaugural guest, Gregg Dalman for a 2025 season preview. Then, Johnny VanDoorn talks about expanding VRD and getting a win with one of the country's top Super Late Model drivers.

In this episode, we dive into the hottest updates in myeloma and amyloidosis at ASH 2024 annual meeting with Dr. Rakesh Popat. Here are the abstracts we discussed: 1. AQUILA Trial in High-Risk SMMOverview of the AQUILA trial testing single-agent daratumumab for high-risk smoldering multiple myeloma (HR-SMM) versus active monitoring. Discussion on patient characteristics, primary endpoints, and results showing significant progression-free survival (PFS) benefit with Dara. Insights into modes of progression, adequacy of active surveillance, and post-protocol therapy in control arm. Read the abstract. Read the simultaneous publication at NEJM. 2. Anito-Cel: New BCMA CAR T Therapy Early data from the iMMagine-1 trial showing strong efficacy and a promising safety profile for Anito-Cel, a novel BCMA CAR T. Discussion of its potential to rival cilta-cel while avoiding neurotoxicity concerns. Read the abstract.3. CARTITUDE-4 Update Updates on MRD-negativity rates and survival outcomes for cilta-cel in relapsed myeloma, with significant benefits over standard care. Read the abstract.4. ANDROMEDA OS Data in AL Amyloidosis Long-term data showing an overall survival (OS) benefit of Dara-VCd over VCd in AL amyloidosis. Insights into cardiac responses and crossover impact. Read the abstract.5. OPTIMUM Trial in Ultra-High-Risk NDMMFive-year follow-up of a tailored approach for ultra-high-risk newly diagnosed myeloma patients with continuous therapy incorporating multiple active agents. Subgroup outcomes highlighting both challenges and exceptional results. Read the abstract6. GMMG-HD7 Trial PFS Update Phase 3 trial results on Isa-VRD vs. VRD induction and risk-adapted tandem ASCT. Discussion on the role of CD38 in maintenance therapy. Read the abstract Read the simultaneous publication at JCO7. Exciting New Drugs Review of three innovative therapies: inobrodib, a BCMA-CD38 trispecific antibody, and cevostamab, a FcRH5-targeted bispecific antibody. Expert insights into their efficacy and potential to reshape myeloma care. Read the abstract

In this episode, we talk about Kandrac & Kole 2.0 or in other words, our plans for 2025, which include some big changes, and our reasons behind what we are doing.  Watch on YouTube: https://bit.ly/InsideDesignYouTube Listen on Apple Podcasts: https://tinyurl.com/26vjfy24 Listen on Spotify: https://spoti.fi/3I46Lve Or wherever you get your podcasts. SPONSORThis episode is sponsored by Vacation Rental Designers, the ultimate resource for interior designers in the short-term rental market. VRD provides education, insight and community for practitioners, along with game-changing product discounts from VRD Sponsors.  Vacation Rental Designers is a membership community founded by our good friend and colleague Jessica Duce. She has a unique perspective on vacation rental design. It's different than normal residential design and even hospitality design.  Vacation Rental Design is its own animal and its ripe for new talent and smart business practices that will be sure to add profit to your design business. To learn more, go to vacationrentaldesigners.com. KANDRAC & KOLE BIOVoted one of “Atlanta's Top 20 Residential Interior Designers” by the Atlanta Business Chronicle, Kandrac & Kole Interior Designs is an acclaimed design firm with two decades of experience serving residential and commercial clients. Their work has been featured in leading publications across the US.  Since 2005, Joann and Kelly have built a respected partnership. They are renowned for their dynamic personalities, distinctive use of color, and unique custom designs. Frequently invited to share their insights at industry events and on design panels, they are recognized as diligent business operators who remain approachable and genuine, radiating constant positive energy.  In 2018, they used their infectious energy to launch their podcast, “Inside Design with Kandrac & Kole.” This lively, weekly conversation, where Joann and Kelly share design and industry insights, became so popular that they introduced a series of bonus episodes, “The Inside Scoop with Joann and Kelly,” in 2024. Their dedication to the power of interior design also extends to their charity work throughout the U.S. and Guatemala.  Thank you Russ Riba with Podcast Studio Network (https://www.audiomenu.com/podcaststudionetwork) and Gayle Mahoney with Gayle Mahoney Branding & Design (www.gaylemahoney.net) for helping us to produce and market this show! SOCIAL MEDIA HANDLES https://www.facebook.com/kandracandkole/ https://www.instagram.com/kandrackole/ https://twitter.com/KandracKole/ https://www.pinterest.com/kandrackole/ www.kandrac-kole.com

La Dra. Nidia Paulina Zapata Canto, hematóloga adscrita al Instituto Nacional de Cancerología en la Ciudad de México, en este episodio de “Preguntémosle al experto…” nos comenta sobre lo más destacado durante ASH 2024. Mieloma múltiple CEPHEUS: Estudio fase III, abierto, aleatorizado 1:1 que evaluó la combinación de daratumumab combinado con bortezomib, lenalidomida y dexametasona (D-VRd), comparándola con el régimen de VRd solo en 395 pacientes con mieloma múltiple recién diagnosticado que no son elegibles para trasplante o para quienes el trasplante se había diferido. El objetivo primario del estudio fue evaluar la tasa de negatividad para enfermedad mínima residual. Linfomas indolentes EPCORE NHL-2: Estudio fase Ib/II en curso de epcoritamab de duración fija + R2, el cual logró respuestas profundas y duraderas en pacientes con linfoma folicular refractario o en recaída: seguimiento a 2 años. Leucemia aguda mieloblástica COMMAND: Impacto del tiempo entre diagnóstico y tratamiento en adultos con leucemia mieloide aguda tratados con agentes hipometilantes y venetoclax: análisis retrospectivo multicéntrico en el mundo real. Linfomas agresivos POLARIX: Un seguimiento prolongado confirma el impacto positivo de polatuzumab vedotina en combinación con rituximab, ciclofosfamida, doxorrubicina y prednisona (Pola-R-CHP) en los resultados a 5 años. Linfoma de Hodgkin RAPID: Radioterapia de campo involucrado frente a no recibir tratamiento adicional en pacientes con linfoma de Hodgkin en etapa 1A o 2A con PET negativo tras 3 ciclos de ABVD: supervivencia y causa de muerte tras un seguimiento de 16 años.  Fecha de grabación: 12 de diciembre de 2024.                           Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.

In newly diagnosed multiple myeloma (NDMM), recent studies highlight the critical role of minimal residual disease (MRD) in guiding treatment decisions and improving outcomes. A significant trial showed that adding isatuximab (Isa) to lenalidomide, bortezomib, and dexamethasone (RVd) increased MRD negativity rates after induction therapy compared to RVd alone. MRD negativity was achieved in 50% of patients receiving Isa-RVd versus 36% in those receiving RVd. Additionally, Isa-RVd provided longer progression-free survival (PFS) in MRD-positive patients, though PFS was similar between Isa-RVd and RVd in MRD-negative patients. This suggests Isa offers a significant advantage for MRD-positive patients.After a median follow-up of 48 months, patients achieving MRD negativity after induction or transplant had significantly better PFS compared to those who remained MRD-positive. The GMMG-HD7 trial, the first phase 3 study to confirm the long-term benefits of achieving MRD negativity with an 18-week induction regimen, demonstrated that deep MRD responses can result in lasting benefits, even without post-transplant consolidation therapy. Future analyses will assess the role of maintenance therapy with or without isatuximab.Another study examined MRD progression (MRD-P) in NDMM patients treated with quadruplet therapy and autologous stem cell transplantation (ASCT). Though rare, MRD-P predicted imminent progression to full disease. Patients with MRD-P had shorter time to progression and poor survival free from failure of second-line therapy. MRD-P was driven by a plasma cell population resistant to existing therapies, including monoclonal antibodies, highlighting the need for new markers and treatment strategies for high-risk patients.The CEPHEUS phase 3 trial evaluated the addition of daratumumab (DARA) to the standard VRd regimen in NDMM patients who were transplant-ineligible or deferred transplant. The D-VRd combination significantly increased MRD negativity rates at both the 10^-5 and 10^-6 sensitivity thresholds and led to sustained MRD negativity in more patients than VRd alone. This deeper response resulted in superior PFS, with over 80% of MRD-negative patients remaining progression-free at 54 months. D-VRd improved outcomes in both MRD-positive and MRD-negative patients, positioning it as a new standard of care for transplant-ineligible or deferred patients.A final study explored whether sustained MRD negativity could allow for discontinuation of lenalidomide maintenance after ASCT. Patients who achieved sustained MRD negativity after three years of lenalidomide maintenance discontinued therapy, with MRD testing every six months. Of the 194 patients, 26.3% achieved sustained MRD negativity, with most remaining MRD-negative for up to 30 months post-therapy. Only 23% became MRD-positive, and a small number progressed to active disease. Among those who restarted lenalidomide, the median time to progression was 9.5 months. This suggests sustained MRD negativity may serve as a marker for safely discontinuing lenalidomide, though further trials are needed to confirm these findings.In conclusion, MRD status plays a vital role in optimizing treatment and improving outcomes in NDMM. From the benefits of isatuximab and daratumumab in enhancing MRD negativity to the possibility of safely discontinuing maintenance therapy, MRD testing is proving essential in multiple myeloma management.Disclosure: Supported by Sanofi.

Welcome to this OncoAlert Session Round Up during ASH24, focusing on Multiple Myeloma pharmacologic therapies.GMMG-HD7 Trial (JCO Publication)This phase 3 trial evaluated adding isatuximab (Isa) to the standard RVd (lenalidomide, bortezomib, dexamethasone) regimen in transplant-eligible patients with newly diagnosed multiple myeloma. Part 1 randomized 662 patients to Isa-RVd or RVd, followed by autologous stem cell transplantation and a second randomization to lenalidomide or Isa-lenalidomide maintenance. Isa-RVd showed higher minimal residual disease (MRD) negativity rates post-transplant (66% vs 48%) and improved progression-free survival (PFS) with a hazard ratio of 0.70 (P = .0184). Isa-RVd plus lenalidomide maintenance further improved PFS (P = .016), underscoring Isa's role in prolonging MRD negativity and PFS.IMROZ Trial (Phase 3)This trial analyzed Isa-VRd (isatuximab, bortezomib, lenalidomide, dexamethasone) versus VRd in transplant-ineligible patients with newly diagnosed multiple myeloma. Isa-VRd led to significant improvements in PFS and deeper, sustained MRD negativity, with 68.6% achieving MRD negativity by month 36 compared to 50.8% in the VRd group. Isa-VRd also resulted in lower MRD loss rates during maintenance and improved conversion from MRD positivity to negativity, leading to longer PFS. These findings highlight Isa-VRd's potential for faster, durable responses and support its use to improve long-term outcomes in these patients.UK MRA Myeloma XI+ TrialThe phase 3 UKMRA/NCRI Myeloma XI+ trial compared KRdc (carfilzomib, lenalidomide, dexamethasone, cyclophosphamide) to sequential triplet therapies (CRd, CTd) in newly diagnosed multiple myeloma patients. After a median follow-up of 102 months, KRdc improved PFS (56 vs 37 months, hazard ratio 0.69, P < 0.001) across cytogenetic risk groups, with higher MRD negativity rates. Early MRD negativity correlated with better PFS. While overall survival was similar in contemporaneously randomized patients (76% vs 71% at 60 months), non-contemporaneous controls showed an overall survival benefit with KRdc (76% vs 68%, hazard ratio 0.80, P = 0.011). These results emphasize the depth of responses with KRdc, particularly for high-risk patients, and the importance of early MRD negativity for improved PFS and survival.DREAMM-7 Trial (Phase 3)This trial compared belantamab mafodotin (BVd) versus daratumumab (DVd), both combined with bortezomib and dexamethasone, in relapsed/refractory multiple myeloma. BVd demonstrated a significant PFS benefit (36.6 vs 13.4 months, hazard ratio 0.41, P < 0.00001), with higher complete response and MRD negativity rates (25% vs 10%). BVd also showed a longer response duration (35.6 vs 17.8 months) and early trends favoring overall survival (84% vs 73% at 18 months). Median overall survival was not reached, but projections estimate 84 months for BVd versus 51 months for DVd. BVd's safety profile included manageable ocular events, positioning it as a promising option for relapsed/refractory multiple myeloma after first relapse.AQUILA Trial (NEJM Publication)This phase 3 trial evaluated subcutaneous daratumumab as monotherapy versus active monitoring in high-risk smoldering multiple myeloma. Among 390 patients, daratumumab reduced the risk of progression or death by 51% compared to monitoring (hazard ratio 0.49, P < 0.001) after a median follow-up of 65.2 months. At five years, PFS was 63.1% in the daratumumab group versus 40.8% in the monitoring group. Overall survival was higher with daratumumab (93.0% vs 86.9%). Daratumumab was well-tolerated, with hypertension being the most common grade 3 or 4 adverse event (5.7%), and no new safety concerns emerged. Daratumumab significantly delayed progression to active multiple myeloma and improved survival in high-risk patients.Disclosure: Supported by Sanofi.

FDA has been busy the last week approving: -ribociclib x 3 years in high risk stage II & III breast cancer based on the NATALEE trial as well as a new storage requirement -osimertinib indefinitely following chemoradiation in stage III EGFR-mutated NSCLC -amivantamab + chemotherapy following progression on osimertinib (Mariposa-2) -a subcutaneous formulation of atezolizumab -isatuximab + VRD for multiple myeloma -pembrolizumab + chemotherapy for metastatic pleural mesothelioma

We are tackling the world of virtual coaching for painful sex, vaginismus, vulvodynia and pelvic floor dysfunction. We'll address the common questions I get about how we can effectively help you remotely. I share insights from my own journey as a pelvic floor physical therapist, from my in-person work to now leading a fully remote team, and how we've been able to help hundreds overcome issues like painful sex, vaginismus, and incontinence through our specialized, virtual care. If you're curious about how virtual coaching works and whether it's right for you, this episode is for you!To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

If you've been struggling with painful sex or feeling anxious about insertion, then listen up baby because this episode is for you. I am discussing the most common challenges women face with dilators, fear of pain, and pelvic floor issues like vaginismus and vulvodynia.  I walk you through the ways we help clients overcome these fears using neuromuscular strategies that retrain the body and calm the mind. It's all about taking that next step to regain control and confidence. The Vagina Rehab Doctor team is here for you on your journey!To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

In today's episode, I dive into the juicy details of boosting your sex drive and libido with five specific foods that can help you feel more excitement and desire in the bedroom—or wherever the mood strikes! If you've been struggling with low libido, poor sex drive, or even sexual pain, this one is for you. I'll share tips on how to increase pleasure and satisfaction naturally. Grab a pen and paper because I want you to take action! Let's get those juices flowing!To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

Are you feeling shame around your pelvic floor dysfunction? Are you scared to talk about your experience around sexual pain or vaginismus? Today I am addressing the importance of releasing shame and secrecy around pelvic floor health issues and sexual dysfunction. I want to encourage you to share your story and understand that you are not alone. We'll talk about how these conditions can affect anyone and how embracing community and support can be the key to overcoming them! Plus, I'll be sharing some exciting details about an upcoming event that could be a game-changer for your journey to healing! Join me, and let's break the silence together.Join my Global Vaginismus Awareness Day Conference on September 15th from 2-6 pm Central Timehttps://the-vagina-rehab-academy.sellfy.store/p/global-vaginismus-awareness-conference/To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

In this episode, we discuss the management of newly diagnosed transplant in-eligible multiple myeloma with Dr. Timothy Schmidt, with a special focus on IMROZ and BENEFIT RCTs testing quadruplets in this space. Here are the key papers we discussed: 1. MAIA trial (Daratumumab-Lenalidomide-Dexamethasone [DRd] vs Rd in newly diagnosed transplant ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/34655533/2. S0777 trial (VRd vs Rd in newly diagnosed myeloma [transplant-ineligible or transplant-deferred]): https://pubmed.ncbi.nlm.nih.gov/32393732/3. IMROZ trial (Isatuximab-VRd vs VRd in newly diagnosed transplant-ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/38832972/4. IFM-2020/BENEFIT trial (Isatuximab-VRd vs Isatuximab-Rd in newly diagnosed transplant-ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/38830994/5. GEM2017FIT trial (VMP-Rd vs KRd vs Dara-KRd in newly diagnosed transplant-ineligible myeloma): https://ashpublications.org/blood/article/142/Supplement%201/209/500199 

In today's episode, I am sharing a topic that I encounter often as a pelvic floor physical therapist specializing in vaginismus and sexual pain. As an expert on this topic I understand how vaginismus, a condition that affects millions, can become a part of your identity and the challenges that come with overcoming it. I want you to know why it's important to recognize that vaginismus is just a phase and how you can start taking steps towards reclaiming your life and confidence. If you're ready to move forward and need guidance, I offer some practical options to help you on your journey. So Listen up y'all when I say vaginismus is not something that needs to define your life. Let's take the first step together.Click to join the Global Vaginismus Awareness Conferencehttps://the-vagina-rehab-academy.sellfy.store/p/global-vaginismus-awareness-conference/To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

In this episode I talk about 2 game changers in the RC arena - Furitek and Vanquish. Furitek has been changing the game in the mini RC platform for years and continue to create new products that take it further. Vanquish has been making next level products for years and their new VRD lineup makes the entry into RC crawling comps much easier for people like me. 

In today's episode, I am sharing something that might be holding you back from experiencing those strong, satisfying orgasms—pelvic floor tightness. I'll be breaking down what it is, how it affects your ability to reach orgasm, and sharing practical tips to help release that tension. If you've been struggling with orgasmic pleasure, this episode is for you. Plus, I've got some exciting news about an upcoming masterclass that could be just what you need to take your sexual satisfaction to the next level. Let's amp up the sexual joy and an orgasmic life! Sign up for the I CUM EASY Orgasm Masterclass on August 25th! FULL RECORDING INCLUDED.Register Here: https://the-vagina-rehab-academy.sellfy.store/p/i-cum-easy-orgasm-masterclass/To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

I'm sharing the crucial role of your pelvic floor in achieving those toe-curling, mind-blowing experiences, and I'll share exercises to help you get there. We'll also touch on the importance of being comfortable discussing pelvic health with friends and how it can impact your overall well-being. Plus, you won't want to miss the details about my upcoming masterclass, "I Cum Easy," designed to help you unlock your full orgasmic potential! Tune in and take a step closer to a more satisfying and pleasurable life!Sign up for the I CUM EASY Orgasm Masterclass August 25thRegister Here: https://the-vagina-rehab-academy.sellfy.store/p/i-cum-easy-orgasm-masterclass/To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

In this episode, I'm diving deep into a topic that's often kept under wraps—orgasms! Today, I'm your sex educator, guiding you through the essentials of reaching your first orgasm or enhancing the ones you're already having. We'll talk about arousal, clitoral stimulation, and how your pelvic floor muscles play a key role in your sexual satisfaction. If you've ever struggled with orgasming or just want to up your game, this episode is for you. Let's get onboard the pleasure train! To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

We're exploring the physical and mental aspects of this brick wall sex sensation & pinpointing which pelvic floor muscles might be to blame. Those of you suffering with vaginismus, vulvodynia and pelvic floor tightness, this episode is for you! We'll get into ways you can turn that brick wall into a smooth, buttery experience, with pain free & pleasurable sex! Whether you've been wrestling with this forever or it's a new challenge, you can reclaim your sexual confidence & get the victory! To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

Hey, hey, hey y'all! In today's episode, we're diving into the fears and anxieties around touching your own vagina, and I don't even mean sexually. We're going to explore why this fear might exist, how to move through it, and the support the Vagina Rehab Doctor team can provide. From understanding your pelvic floor to practical steps you can take at home, we'll cover it all. Let's get into how you can take control and overcome these challenges together. To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

Hey y'all! In today's episode, we dive deep into some pretty intriguing topics: anal sex, Botox for pelvic floor muscle dysfunction, hymenectomies, and the idea of a side chick for those struggling with painful sex. We'll explore the ins and outs of these issues, provide practical advice, and share some real-life stories from my clients. I want to be real with you as we navigate these often-taboo subjects together. Tune in and let's get into it—because it's time to get comfortable with being uncomfortable!To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

We are diving deep into the sensitive yet crucial topics of sexless and unconsummated marriages and exploring the nuances between these two states, the barriers to sexual intimacy, and most importantly, actionable steps to reignite and transform your intimate relationship. Whether it's pain, fear, or physical tension that's holding you back, I'm here to guide you towards a fulfilling and connected sexual partnership. Tune in for an honest, unapologetic conversation and find out how you can move from a sexless marriage to one filled with love, intimacy, and passion.To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

Hey y'all! We are getting real about the crucial connection between mental health and pelvic floor dysfunction. We'll explore how anxiety, trauma, and stress can affect your pelvic health and share practical tips on managing these issues. Remember, you don't need a mental health diagnosis to seek support—everyone can benefit from understanding and improving their mental well-being. We're in this together so stay tuned and learn how your mind and body are intertwined and what you can do to feel better and more connected. To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

Hey y'all!  In today's episode, we're diving deep into a topic that many of you have asked about: how long does it take to beat vaginismus and other pelvic pain conditions? We're exploring everything from the common struggles and symptoms to the realistic timelines for recovery. Whether it's difficulties with penetration, vulvodynia, or pelvic floor issues, we're here to talk about the hope and real progress you can make. Remember, this journey is about improving your quality of life and feeling connected to your body. To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

Drs. John Sweetenham and Marc Braunstein discuss practice-changing studies in hematologic malignancies that were featured at the 2024 ASCO Annual Meeting, including the ASC4FIRST trial in chronic myeloid leukemia and IMROZ and CARTITUDE-4 in multiple myeloma.  TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center and host of the ASCO Daily News Podcast. On today's episode, we'll be discussing practice-changing abstracts and other key advances in hematological malignancies that were featured at the 2024 ASCO Annual Meeting. Joining me for this discussion is an old friend, Dr. Marc Braunstein, a hematologist and oncologist from the NYU Langone Perlmutter Cancer Center.  Our full disclosures are available in the transcript of this episode. Marc, it's great to have you back on the podcast again. There were some important studies in the heme space at the Annual Meeting this year, and we're very pleased that you're able to share your takeaways.  Dr. Marc Braunstein: Thank you, John. It's great to be back again. Dr. John Sweetenham: Let's start out, Marc, with LBA6500. This abstract reports the primary results of the ASC4FIRST trial, and this was a trial comparing asciminib with investigator selected tyrosine kinase inhibitors in newly diagnosed patients with chronic myeloid leukemia. Could you tell us a little about the trial and how you think it's going to impact clinical practice? Dr. Marc Braunstein: Absolutely. So, asciminib is an oral tyrosine kinase of the ABL kinase domain. As we know in CML, the BCR-ABL translocation is characteristic of the disease, and asciminib is approved for chronic phase CML with a T315I resistance mutation or for patients who have received 2 or more prior lines of therapy. So the ASC4FIRST trial was a randomized trial of 405 patients with newly diagnosed chronic phase CML who are randomized one to one to receive either asciminib at 80 milligrams once daily, or investigator's choice of a first generation TKI imatinib or one of three second generation TKIs nilotinib, dasatinib, or bosutinib. The primary endpoint of the study was the major molecular response, or MMR, at 48 weeks. Pretty much, the study met its primary endpoint with a 67% rate of MMR at 48 weeks, with asciminib versus 49% in patients treated with the investigator's choice of TKI. And in addition, the major molecular remission or MMR of 4.5, which is a deep remission, those rates were higher as well, with asciminib versus investigator's choice at a rate of 39% versus 21% when comparing the groups. Furthermore, when we looked at toxicity, there were fewer grade 3 or higher adverse events, with the asciminib at 38% versus either 44% with the first generation, or 55% with the second generation TKI, and fewer discontinuations as well with asciminib.  So I think this abstract is practice-changing. I think it offers compelling data to use asciminib upfront for chronic phase CML. Those who don't agree with that sentiment might argue that we want to see longer term follow up. There's a planned follow-up at 96 weeks. We would want to see the rate of progression to acute myeloid leukemia and of course overall survival as well. But I think the abstract certainly shows an improvement in outcomes with asciminib versus our current array of TKIs. Dr. John Sweetenham: Yeah, I think it certainly is, at least at minimum, potentially practice changing. I agree with you. Just one question, and this may be a little bit speculative, but do you have any thoughts about treatment free survival with asciminib and how that might line up against some of the other TKIs? Dr. Marc Braunstein: Yeah, that's a great question. The abstract did not necessarily address that, patients were treated until progression, but we know that with the current landscape of TKIs, that in patients who have achieved a deep MR of 4 or 4.5 for at least 2 years who discontinue their TKI, the rate of relapse is about 50%. The current study, the ASC4FIRST, doesn't address that, but I think it's a really good question about whether, for those patients who have achieved a deep remission, whether they can eventually stop asciminib down the line. Dr. John Sweetenham: Yeah, I guess it's one of those ‘watch this space' things.  So we'll see how the data mature out. And let's move on to what I think is another potentially practice-changing study, at least in certain parts of the world. And that's [the] LBA7000 study in classical Hodgkin lymphoma. As you remember, this was a German Hodgkin lymphoma study group trial which looked at the tolerability and efficacy of a novel regimen, BrECADD versus eBEACOPP for patients with advanced stage classical Hodgkin lymphoma in their study, which is known as GHSG HD21. Can you give us your thoughts and take home messages from this trial? Dr. Marc Braunstein: Yeah, John, absolutely. So the German HD21 study is a phase 3 study of 1,500 patients with classical Hodgkin lymphoma. The majority were stage 3 or 4, 84%, that compared two regimens BEACOPP to BrECADD. The major difference between these 2 groups being that the newer BrECADD regimen swaps out bleomycin for brentuximab vedotin, which is an anti-CD30 antibody drug conjugate. Also, in the BrECADD regimen they eliminate vincristine that's incorporated into BEACOPP. Those are kind of the global differences between these 2 regimens. And when comparing these, they looked at the primary endpoint of progression-free survival. Of note, in this study there was a PET adjusted approach where if patients achieved interim PET negativity after 2 cycles, that was followed by an additional 2 cycles of their treatment as opposed to 4 cycles if they were PET positive after the initial 2 cycles of their respective treatment. And of note, there were similar rates of PET2 negativity between both arms, about 58% in both arms.  So at a median follow-up of 48 months, the 4-year progression-free survival was significantly better with the brentuximab containing BrECADD regimen at 94% versus 91% with a hazard ratio of 0.66. And the overall survival of the BrECADD arm was 98.6%, which is very high and impressive. The 4-year overall survival was similar between the arms at around 98%, but of note, there were fewer severe adverse events with BrECADD, the brentuximab containing arm versus BEACOPP at about 42% versus 59% and interestingly less peripheral neuropathy with the brentuximab containing BrECADD. So we're doing extremely well in treating advanced stage classical Hodgkin lymphoma. So the bar is set very high. But in this study, the rates of progression-free survival and overall survival are very impressive.  While these intensive regimens tend to be used outside of the U.S., there are several notable benefits of the study, including greater than 50% PET2 negativity and high rates of progression-free survival at 4 years. In discussing this abstract, it's worth noting that there are other competing regimens, if you want to call it that, that are more commonly used in the U.S. So the ECHELON-1 study looked at brentuximab AVD compared with ABVD with bleomycin and it was a 94% versus 89% 6-year overall survival rate favoring the brentuximab containing A+AVD regimen. And lastly, more recently, the SWOG S1826 study that hasn't been published but was presented in abstract form looked at nivolumab AVD versus brentuximab AVD at a median follow up of 12 months showed a progression-free survival of 94% versus 86%. And that study still has yet to be published and needs to mature. But both of those regimens are in the NCCN guidelines. So, we're definitely pushing the bar higher in terms of improving responses in treating advanced classical Hodgkin lymphoma. Dr. John Sweetenham: I think that there's no question that these results from BrECADD are very impressive. But I'm taken back to what I think has been a kind of philosophic discussion in Hodgkin lymphoma now for a number of years about balancing disease control and efficacy against the potential short-term and long-term toxicity of the regimens, particularly when you have very effective salvage therapies for those patients who may suffer a relapse. So I think that this is a discussion over whether you take a very intensive, upfront approach to Hodgkin lymphoma versus something that may be less and slightly less intensive. I suspect that's a discussion that's going to continue for a long time. I don't know what you feel, but my own feeling about this is that this study will likely have a major influence over treatment of Hodgkin lymphoma, particularly in western Europe. Less likely in the US.., I would think. I don't know what your thoughts about that are. Dr. Marc Braunstein: Well, it's a great question. In SWOG S1826, that study did include pediatric patients. In HD21, the median age was 31 and did not include pediatric patients. So I think we have to be selective in terms of fitness and which patients may be better suited for different regimens. But I think what all these studies show is certainly when we incorporate novel immunotherapies, whether it's brentuximab vedotin, nivolumab, we improve progression-free survival and even overall survival. Dr. John Sweetenham: Absolutely.  So let's shift gears now and take a look at Abstract 7500, the IMROZ study. This was the study of isatuximab, bortezomib, lenalidomide and dexamethasone versus VRD alone for transplant ineligible patients with newly diagnosed multiple myeloma. I know we discussed this in our preview podcast a few weeks back, Marc, but I just wonder now, having seen the data in more detail, what do you think of the important takeaways? And again, are we looking at a new standard of care? Dr. Marc Braunstein: You know, there are many standards of care in multiple myeloma, but we're always looking to make improvements on the regimens we have at our disposal. So, just to recap, IMROZ is a phase 3 randomized study of the anti-CD38 monoclonal antibody isatuximab with the backbone of bortezomib, lenalidomide, dexamethasone or VRD versus VRD alone, specifically, in transplant ineligible newly diagnosed multiple myeloma patients age less than 80. They studied 446 patients in this study, randomized 3 to 2 to Isa-VRD versus VRD alone, with the primary endpoint of progression free survival. Now, similar to other studies where they included a monoclonal antibody up front, the study met its primary endpoint of improving progression-free survival with the quad regimen containing the monoclonal antibody isatuximab versus VRD alone.  So what was interesting about the study, it's really the first of its kind to be presented that specifically looked at transplant ineligible patients, which is presumably a less fit or perhaps more frail population that wouldn't go on to consolidation with stem cell transplant. And in this study, the progression-free survival at 5 years was 63% versus 45%, clearly superior when you included isatuximab. And the rates of complete remission and MRD negativity were all significantly improved, too. However, that was also met with slightly more grade 3 or higher treatment emergent adverse events, 92% versus 84% in the control arm. There are also 11% grade 5 treatment emergent adverse events with the isatuximab group versus 5.5% with VRD alone. Although there was no major difference in treatment discontinuation. One small caveat worth noting, too, is that high-risk patients in this study, when presented at ASCO, did not necessarily show a difference in benefit, although there wasn't necessarily a detriment either.  So, John, I think that clearly quadruplet regimens are superior in outcomes of efficacy to triplets, even in transplant-ineligible patients. But I think we have to tailor these treatments to individual patients because I think when it comes to transplant-ineligible patients, it's a spectrum of patients who may be more or less fit for quad regimens versus triplet regimens. It's also worth noting, though, that in this study, the patients are really only getting a quad regimen for 4 cycles. They get their Isa-VRD, and then you drop the bortezomib.  So when we think about quads, it's not that they're getting the quad regimen indefinitely, it's really for the induction cycles. But still, I think we have to be aware of potential safety issues. Dr. John Sweetenham: Okay, great. And let's stay on the theme of multiple myeloma, Marc, and talk a little bit about Abstract 7504, which was a subgroup analysis of the CARTITUDE-4 study. This is a report on the use of ciltacabtagene autoleucel versus standard of care in patients with functional high risk multiple myeloma. Can you give us your thoughts on this and maybe put it into a bit of context for us?  Dr. Marc Braunstein: Absolutely, John. It's really a great time to be in the field of multiple myeloma. We're making tremendous progress, but when we think about one of the unmet needs, it's just consistently the high-risk patients who have shorter responses and are at higher risk for poorer outcomes. Just to review, cilta-cel is one of the 2 available anti-BCMA CAR T-cell products available for the treatment of relapsed or refractory multiple myeloma. Very recently, the FDA approved cilta-cel for lenalidomide refractory patients after 2 or more prior lines of therapy based on the CARTITUDE-4 study, which was published by San-Miguel and colleagues in New England Journal of Medicine in July 2023. And that study randomized 419 patients with multiple myeloma with 1 to 3 prior lines of therapy to receive either cilta-cel or physician's choice of standard of care, which was either 1 of 2 triplet regimens, a pomalidomide, bortezomib, dexamethasone or daratumumab, pomalidomide and dexamethasone. It's worth noting that about 25% of the patients in the CARTITUDE-4 study had prior anti-CD38 antibody treatment previously and the carfilzomib was not included in one of the standard-of-care arms, and we know that those regimens containing carfilzomib do increase survival in relapsed myeloma.  Nevertheless, the primary outcome of progression-free survival was not reached in the CAR T-cell arm versus 11.8 months in the standard-of-care arm, with a significant reduction in progression of 74%. So clearly a positive study and CAR T-cell therapy is included in the NCCN guidelines for patients who have an early relapse from their myeloma. The current abstract by Costa et al focused specifically on a subgroup of 79 patients from CARTITUDE-4 in second line of treatment and looked at what they called functional high-risk myeloma, defined as progression of disease within 18 months of initial treatment or after stem cell transplant. Again, the study showed a retained benefit of cilta-cel with significant improvement in progression-free survival either not reached or 12 months with the control standard of care arm, as well as complete remission rate and rates of MRD negativity of 65% versus 10% in the control.  The overall survival outcome was still immature and not presented. Nevertheless, cilta-cel is clearly superior to standard-of-care triplet regimens. I think that for patients with high risk, they clearly derive a benefit from CAR T-cell therapy if they have short progression-free survival after initial therapy.  Dr. John Sweetenham: Thanks, Marc. So let's round this out by talking about another area of unmet need, I guess in a way in a difficult to treat patient group. And that's Abstract 7007, the SYMPATICO study. This is a study which looks at the efficacy and safety of ibrutinib and venetoclax in patients with mantle cell lymphoma who had a mutated TP53. Can you just briefly review this for us and tell us what you think we should be taking away from this studys? Dr. Marc Braunstein: So, mantle cell lymphoma typically has an aggressive behavior, but the subgroup of patients with a P53 mutation tend to have the poorest outcomes and do represent an area of unmet need. Although BTK inhibitors are making important improvements in mantle cell lymphoma, they have yet to be approved in newly diagnosed mantle cell lymphoma. Acalibutinib and zanubrutinib are FDA-approved BTK inhibitors for previously treated mantle cell lymphoma. Ibrutinib was withdrawn from the market in the U.S. for mantle cell lymphoma. Dr. Michael Wang's group presented late-breaking data from the phase 3 SYMPATICO trial at ASH 2023, in which 267 patients with relapsed refractory mantle cell lymphoma were randomized to receive either ibrutinib plus the BCL2 inhibitor venetoclax or ibrutinib plus placebo after 1 to 5 prior lines of therapy. And that study showed a 32 versus 22 months progression-free survival at a median follow up of 51 months. The current abstract, also by Dr. Wang and colleagues, looked at the subgroup of patients who had a P53 mutation and included an open label cohort of 44 patients in the first line of treatment and a relapse refractory cohort of 75 patients, and compared this subgroup of patients with P53 mutation to those without. When we look at the outcomes, the patients who did not have a P53 mutation clearly did better in terms of progression-free survival being not reached in first-line treatment compared to 22 months progression-free survival in those patients with first-line [treatment] with a P53 mutation. As well as in the relapsed refractory setting, the PFS without the P53 mutation was 47 months versus 21 months with the mutation. However, when you look at these patients treated with ibrutinib and venetoclax comparing whether they got treated in first line or the relapse refractory setting, the overall response rates are very similar at about 80% to 90% and the CR rates were very similar at about 55% to 58%, which to me suggests that although patients with P53 mutation do worse than those without it, whether they're treated in the first-line or the relapse setting with this combination of venetoclax, they tend to do somewhat similar, suggesting that you can overcome resistance to prior therapy in the relapse setting. So I think further data are certainly warranted to explore the role of combination therapies that include novel agents such as BTK inhibitors in the first line setting.  It's worth noting that the TRIANGLE study was recently published, and this study looked at including ibrutinib at various phases, including at induction in combination with intensive chemotherapy and during the maintenance phase. And that study showed encouraging outcomes in patients who received ibrutinib even without stem cell transplant compared to those who received stem cell transplant. So the role of BTKIs in mantle cell lymphoma is certainly evolving, and I think it offers a very effective intervention without the same kind of toxicities we see with cytotoxic chemotherapy that's traditionally used in mantle cell lymphoma. But I think the subgroup of patients with P53 mutation in this disease still represent an area of unmet need that unfortunately have worse outcomes. But novel agents may be able to overcome some of those adverse outcomes. Dr. John Sweetenham: Yeah, I agree. I think these are intriguing data, and obviously it needs more follow-up and probably more prospective studies. But nevertheless, I think there are some signals there for sure that need to be followed up on.  Marc, as always, it's great to have your insights on key advances in the heme space from ASCO. An important year this year, and we really appreciate your time and effort in sharing with us your thoughts on what we've learned this year. So thank you as always. Dr. Marc Braunstein: My pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstract discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest:  Dr. Marc Braunstein  @docbraunstein    Follow ASCO on social media:   @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn     Disclosures:  Dr. John Sweetenham:  Consulting or Advisory Role: EMA Wellness  Dr. Marc Braunstein:  Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp  Speakers' Bureau: Janssen Oncology  Research Funding (Institution): Janssen, Celgene/BMS   

Hey y'all! We're diving deep into the often-overlooked topic of libido and uncovering some secret causes behind low sex drive. We'll talk about the importance of proper nutrition, managing pain, and reducing stress to help boost your sexual desire. Listen up because I am sharing practical tips and personal insights to help you feel empowered and more connected to your sexuality. Let's get into it!To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

Welcome to this Hematology Round Up from #EHA24WE have focused on on Hematologic malignancies with abstracts presented on June 15nd, 2024The first presentation was abstract s100 This Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ) . Presented by Dr. FaconThis trial presentation had a concomitant publication on the @NEJMat #ASCO24 last weekhttps://lnkd.in/d2dRh6HpThe Second presentation was abstract S101THE LANDSCAPE OF TP53 MUTATIONS AND THEIR PROGNOSTIC IMPACT IN CHRONIC LYMPHOCYTIC LEUKEMIAhttps://lnkd.in/dYg6DqPTThe Next presentation was abstract S102FIRST RESULTS OF THE APOLLO TRIAL: A RANDOMIZED PHASE III STUDY TO COMPARE ATO COMBINED WITH ATRA VERSUS STANDARD AIDA REGIMEN FOR PATIENTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE PROMYELOCYTIC LEUKEMIAhttps://lnkd.in/d2ZM6Z4QThe Next presentation is abstract S103ASCIMINIB (ASC) PROVIDES SUPERIOR EFFICACY AND EXCELLENT SAFETY AND TOLERABILITY VS TYROSINE KINASE INHIBITORS (TKI) IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) IN THE PIVOTAL ASC4FIRST STUDYhttps://lnkd.in/dxiets8mOur final Presentation is Late breaking abstract 3438GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (GLOFIT-GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS OF A GLOBAL RANDOMIZED PHASE III TRIAL (STARGLO)https://lnkd.in/dMWxnyF4Thank you for your attention and enjoy #EHA24Disclosure: This Hematology Round Up was supported by Sanofi

Today we delve into a crucial topic: overcoming vaginismus using dilators. I'll guide you through understanding how these tools can transform your experience with pain, intimacy, and pelvic health. Whether it's painful pap smears, difficulties with tampons, or challenges in your sex life, we'll explore practical strategies to regain control and comfort. Grab your notebook, because this episode is packed with essential insights and steps to help you on your journey. Let's get started and tackle this together!To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

Today I am here to empower your sexual wellness journey. We are discussing a game-changer in the bedroom: lubricants. We'll explore the transformative impact lubes can have, not just for enhancing pleasure but also for those struggling with conditions like vaginismus or sexual pain. I'll guide you through choosing the right lube for different needs, such as using dilators or simply spicing things up. Remember, everything shared is for educational purposes to help you make informed decisions about your body. Let's get you comfortable and confident in your intimate experiences, without the medical jargon. Tune in as we get slippery with science!To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

Dr. John Sweetenham shares highlights from Day 4 of the 2024 ASCO Annual Meeting, including exciting new data from the IMROZ trial in multiple myeloma, adjuvant therapy for triple-negative breast cancer in A-BRAVE, and the front-line treatment of advanced renal cell carcinoma in JAVELIN Renal-101. TRANSCRIPT Dr. John Sweetenham: I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast, with my top takeaways on selected abstracts from Day 4 of the 2024 ASCO Annual Meeting.   Today's selection features 3 randomized prospective trials in the first-line treatment of multiple myeloma, adjuvant therapy for triple negative breast cancer, and the frontline treatment of advanced renal cell carcinoma, all of which provide important new data.   My full disclosures are available in the transcript of this episode. The first of today's abstracts is number 7500. This abstract, presented by Dr. Thierry Facon from the Department of Hematology at the University of Lille in France, describes the results of the IMROZ study. This was a multicenter phase 3 study comparing a current standard first-line regimen for transplant ineligible patients with myeloma VRd with the same combination plus an additional agent, isatuximab.  The combination of bortezomib, lenalidomide and dexamethasone, known as VRd, is currently a standard first-line regimen for patients with multiple myeloma, both transplant eligible and ineligible. Previous phase 3 studies have shown that the addition of an anti-CD38 antibody to triplet regimens improves outcomes in newly diagnosed patients. Based on early phase clinical trial data showing promising response rates with isatuximab, the IMROZ study was conducted to compare isatuximab VRd with VRd alone in patients who were either ineligible for transplant or had no immediate indication for transplant. IMROZ was a global study conducted in 21 countries that involved 446 patients randomly assigned 3:2 to induction therapy with Isa-VRd followed by continuous Isa-Rd or induction therapy with VRd followed by Rd alone. The rate of complete response or better was approximately 75% with Isa-VRd compared with 64% with VRd alone. Very good partial response or better was achieved in 89% of patients with Isa-VRd, compared with around 83% of those with VRd alone. With a median follow-up at 5 years, Isa-VRd followed by Isa-Rd had reduced the risk of progression or death by 40.4% compared with VRd alone. The 60-month progression-free survival rate was 63% for Isa-VRd compared with around 45% with VRd alone, and the progression-free survival benefit was maintained in most of the analyzed subgroups. Minimal residual disease negativity was also measured in this study in both the intent to treat population and those patients who achieved a complete response. For example, in the intent to treat population, the MRD negative rate was 58% with Isa-VRd compared with around 43% with VRd alone. There were also higher rates of sustained MRD negativity for 12 months or longer among patients assigned to Isa-VRd compared with VRd alone, reflecting deeper responses in the Isa-VRd arm. Although overall survival data is still immature, data from an interim analysis showed a favorable trend in the Isa-VRd arm with 22.4% risk reduction compared with VRd alone. There was little additional toxicity from the inclusion of isatuximab with the VRd regimen and the quality-of-life data were comparable and stable in both arms of the study. The investigators concluded that although overall survival data are immature, there is a trend in favor of Isa-VRd and this, combined with the favorable response, toxicity and progression-free survival data, establish isatuximab VRd as a potential new standard of care for newly diagnosed multiple myeloma patients not eligible for transplant. There was some discussion regarding the potential use of this regimen in patients over 80 years of age since the upper age limit was capped in IMROZ at 80 years. Although there are concerns for tolerance of the 4-drug regimen in the older patient group, it seems likely that this will be adopted, especially for those with good performance status and without major comorbidities.   Next up is LBA500. This abstract reports results of the A-BRAVE trial. This trial, presented by Dr. Pier Franco Conte from the University of Padova, Italy, was a phase 3 randomized trial to assess the efficacy of the immune checkpoint inhibitor avelumab in 2 groups of patients: those with early triple negative breast cancer, with residual disease after neoadjuvant chemotherapy; and those at high risk after primary surgery and adjuvant chemotherapy. As Dr. Conte explained in the introduction to this trial, there is a fairly compelling rationale for the use of checkpoint inhibitors in triple negative breast cancer. The disease has been shown to be more immunogenic than the other breast cancer types with immune biomarkers such as TILs and PDL-1 expression associated with better prognosis, added to which, data in metastatic breast cancer show a correlation between PDL-1 expression and checkpoint inhibitor response. In the A-BRAVE study, 477 high risk patients who had completed local, regional, and systemic treatment with curative intent were stratified according to adjuvant or post neoadjuvant status and randomized 1:1 to receive avelumab at 2-week intervals for 52 weeks or to observation only. Results of the study showed a non-statistically significant improvement in three-year disease-free survival in the overall intent to treat population at 5.1% and in the post neoadjuvant patients at 6.2%. Overall survival was a secondary endpoint in this trial. The results show a significant improvement in overall survival of 8.1% in the intent-to-treat population and a very similar improvement in the post-neoadjuvant patients. The authors reported good tolerance of avelumab, although in total almost 30% discontinued treatment at some point. In their conclusion, the investigators state that the 34% reduction in the risk of death suggests a potential role for avelumab in early triple negative breast cancer patients at high risk after primary surgery or with invasive disease after neoadjuvant chemotherapy. Correlative studies are planned on tumor plasma and feces in this study. These are interesting and somewhat tantalizing results, suggesting a real effect from avelumab. Although confounded somewhat by the sample size, it will be important to see how these results mature with further follow-up.   Today's third selected abstract is number 4508 reporting the final analysis of the JAVELIN Renal 101 phase 3 trial in patients with advanced renal cell carcinoma. This study compared the combination of axitinib plus avelumab with sunitinib in this patient group. The trial included 886 patients, of whom around 61% of those in the combination group and around 65% of those in the monotherapy group were PDL-1 positive. In the initial analysis from the JAVELIN Renal 101 study, after at least 6 months of follow-up, avelumab and axitinib significantly improved progression-free survival over sunitinib in patients with PDL-1 positive tumors and in the overall population with advanced renal cell carcinoma. In the fall cohort, the median progression-free survival with the combination was 13.8 months compared with only 8.4 months with sunitinib, and based on those results, the combination received FDA approval as a first-line treatment for patients with advanced renal cell carcinoma in May of 2019. The progression-free survival observed in the initial analysis was confirmed with a new long-term analysis in the overall population. Median progression-free survival with avelumab and axitinib was 13.9 months compared with only 8.5 months with sunitinib and the median duration of response with the combination was 19.4 months versus 14.5 months with sunitinib. However, no difference in overall survival was seen. At 60 months, the overall survival in the combination group was 38.8% and 36.2% with sunitinib. In patients who were PDL-1 positive at 60 months, overall survival with a combination was 37.1% compared with 33.4% with sunitinib.  Despite the sustained difference in progression-free survival seen with this combination, the discussant at this session pointed out that most oncologists are unlikely to recommend a combination which has not been shown to improve overall survival when published studies have reported on 4 combinations which do positively impact overall survival in this patient group. Despite the good tolerance of this regimen, it seems unlikely to be a preferred frontline regimen in advanced renal carcinoma moving forward.  That concludes today's report. Thanks for listening and we hope you have enjoyed listening to our top takeaways from ASCO24. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review and subscribe wherever you get your podcasts.   Disclaimer:  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow ASCO on social media:   @ASCO on Twitter  ASCO on Facebook  ASCO on LinkedIn    Disclosures: Dr. John Sweetenham: Consulting or Advisory Role: EMA Wellness

Go here for complete show notes.   Visit learnAMAstyle.com for free downloads on medical writing and editing Nascentmc.com for medical writing assistance for your company.   mRESVIA for Lower Respiratory Tract Disease The FDA approved mRNA-1345 (mRESVIA) for preventing RSV-caused lower respiratory tract disease in adults 60 and older, based on Phase 3 trial results showing 83.7% efficacy and no serious safety concerns.  Breyanzi for R/R MCL The FDA approved lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory mantle cell lymphoma (MCL) after at least two prior therapies, demonstrating an 85.3% overall response rate in trials. Sarclisa for ND MM The FDA accepted the sBLA for isatuximab (Sarclisa) combined with VRd for treating transplant-ineligible newly diagnosed multiple myeloma, showing significant improvement in progression-free survival. Onyda XR for ADHD The FDA approved clonidine hydrochloride (Onyda XR) for treating ADHD in pediatric patients aged 6 and older, as a liquid nonstimulant medication with common side effects like somnolence and sedation. Bkemv for PNH and aHUS The FDA approved eculizumab-aeeb (Bkemv) as the first interchangeable biosimilar to eculizumab for treating PNH and atypical hemolytic uremic syndrome, requiring meningococcal vaccination prior to use. Austedo in Huntington's The FDA approved a new once-daily tablet option for deutetrabenazine (Austedo XR) for tardive dyskinesia and chorea in Huntington's disease, enhancing treatment flexibility and adherence based on long-term safety and effectiveness data.  

Dear Colleagues,Welcome to this Hematology Round Up from hashtag#ASCO24 . WE have focused on Hematologic malignancies with 3 presentations which were presented on June 2nd, 2024The first presentation was the Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ) . Presented by Dr. FaconThis trial presentation came with a concomitant publication on the New England Journal of Medicine (NEJM).https://lnkd.in/d2dRh6HpThe Second Presentation was the Phase 3 randomized BENEFIT study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI). Presented by Dr. LeleuThis trial presentation came with a concomitant publication on Nature Medicinehttps://lnkd.in/dSjVvk7XThe final presentation was Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial. Presented by Dr Rodriguez-OteroDr. Landgren discussed how quadruple therapies showed higher rates of minimal residual disease (MRD) and longer progression-free survival compared to triplets, regardless of age and transplant eligibility, potentially making them a new standard of care for newly diagnosed Multiple Myeloma.He emphasized the importance of minimal residual disease as an endpoint in newly diagnosed multiple myeloma, suggesting that having it as an early endpoint for accelerated approval could give patients faster access to new therapies. However, he also highlighted that bortezomib increases the rate of peripheral neuropathy.Dr. Landgren pointed out that CD38 monoclonal antibodies narrow the gap between transplant-eligible, younger, and fit patients, and transplant-ineligible, older, and less fit patients with multiple myeloma.Thank you for your attention and enjoy ASCODisclosure: This Hematology Round Up was supported by Sanofi

Hey hey y'all, welcome back! We are diving into a fascinating topic that intertwines your career with sexual health. We won't just be talking about pelvic floor relaxation or pain-free intimacy—though I love those topics! Instead, we're exploring how healing from vaginismus not only transforms your personal life but can dramatically influence your professional life too. I'll share stories from past clients who've found that overcoming this condition boosted their career performance and advancement. Intrigued by how deep-seated personal challenges can impact your work? Join me in this insightful discussion that might just change the way you view your career and personal health journey. Let's get into it! To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

Hey y'all! Today's episode is all about enhancing your pelvic and sexual wellness with nature's gifts—herbal teas. We're diving into my top five picks that could help you thrive in your daily life, especially if you're dealing with issues like heavy periods, painful periods, painful sex, or just wanting to feel more confident in your body. From the powerful antioxidants, to the hormonal benefits, I'm sharing these natural remedies without giving away all the details—you'll have to listen in for the full brew! So grab your cup, tune in, and let's steep into wellness together.To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

Hey, hey, hey, y'all—Janelle here, your go-to pelvic floor physical therapist! Welcome back to another empowering episode of the Vagina Rehab Doctor podcast. Today, we're diving into the transformative world of pelvic floor health and its profound impact on our daily lives—from dining out with friends to enjoying vacations without discomfort. I'm thrilled to share some DIY self-healing strategies for issues like vaginismus and incontinence, aimed at enhancing your pelvic floor muscles' relaxation and functionality. We'll explore everyday actions you can integrate into your routine to foster pelvic health. Remember, improving our pelvic health enhances our overall quality of life, so let's make the most of these insights and start making a difference today! Let's get into it! DM me the words “Coaching” on Instagram @vaginarehabdoctor to get a free 20-30 free consultation call where you can share with me your struggles and goals in overcoming painful sex, tight pelvic floor muscles or vaginismus.To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

Hey y'all! We are diving into the world of orgasms and how to significantly boost your sexual satisfaction. I'm here to guide you through understanding the intricate role of pelvic floor muscles in enhancing the intensity of your orgasms and overall sexual pleasure. We'll explore practical steps to nurture these crucial muscles and share insights on the profound benefits of being in tune with your body's sexual responses. So whether you're struggling with weak orgasms, no orgasms or just seeking to elevate your sexual wellness, this episode is packed with empowering knowledge and actionable advice. Tune in and let's unlock the secrets to a more satisfying sex life!To work with a VRD pelvic floor physical therapist 1 on 1 to help you overcome vaginismus, sexual pain, and pelvic floor dysfunction then click here to schedule a free consult with me: https://calendly.com/d/cn6f-4vw-353/1-on-1-complimentary-vaginal-fitness-screening-session Or email me with any questions you have about our coaching program: janelle@vaginarehabdoctor.com Follow me on social media @vaginarehabdoctor Join my private email club: https://www.vaginarehabdoctor.com/join-my-private-pelvic-floor-email-club/ Produced by Light On Creative Productions

In this episode, we discuss the key abstracts in myeloma and related plasma cell disorders at ASH23 with Dr. Benjamin Derman. Here are the abstracts discussed in this episode: First, we will focus on a few abstracts in precursor states, MGUS. 1.      New diagnostic criteria for light chain MGUS (IStopMM):              https://ash.confex.com/ash/2023/webprogram/Paper188547.html             https://ash.confex.com/ash/2023/webprogram/Paper182661.html2.     PERSEUS Trial-Dara-VRD vs VRD in newly diagnosed transplant-eligible myeloma: https://ash.confex.com/ash/2023/webprogram/Paper191911.html 3.     ISKIA trial: Isa-KRD vs KRD in newly diagnosed transplant-eligible myeloma: https://ash.confex.com/ash/2023/webprogram/Paper177546.html 4.     Phase 1/2 study for Daratumumab-Venetoclax-Dexamethasone in early relapsed t(11;14) myeloma: https://ash.confex.com/ash/2023/webprogram/Paper180766.html 5.     GMMG Relapse Trial (Long-term follow-up data from randomized controlled trial of salvage transplant in myeloma) https://ash.confex.com/ash/2023/webprogram/Paper178835.html 6.     Overall survival results of KarMMa-3 trial https://ash.confex.com/ash/2023/webprogram/Paper178933.html 7.      GEM2017FIT Trial: Dara-KRd vs KRd vs VMP-RD in non-transplant eligible patients: https://ash.confex.com/ash/2023/webprogram/Paper179866.html      

Nella quarta puntata della stagione 8.News dal futuroi mattoni della vita trovati in un asteroidenuovo tipo di mano bionicastrumenti per combattere le fake newsauto elettriche a Stoccolmaaffitti brevi a New York dopo la nuova legge "anti" AirbnbExtreme future:virtual retinal displaysRetro-futureun aneddoto su Ronald McNair, astronautaDal blogAI generativa a rischio bollaHome - The Future Of (the-future-of.it)Le 10 grandi domande sul futuro: Conversazioni virtuali con i Maestri dell'innovazione del passato eBook : Ferrante, Andrea Marco: Amazon.it: Kindle Store

In this episode, we discuss with Dr. Martin Kaiser how to identify and manage newly diagnosed high-risk multiple myeloma in the current era of effective frontline therapies.  Here are the key studies that we touched upon:1. Phase II OPTIMUM (MUKnine) trial in ultra-high-risk myeloma and PCL:https://pubmed.ncbi.nlm.nih.gov/37315268/ 2. Meta-analysis of >2500 patients with chromosome 1q21 abnormalities:https://pubmed.ncbi.nlm.nih.gov/34092058/ 3. Predicting ultra-high risk myeloma by molecular profiling (including SKY92 GEP signature):https://pubmed.ncbi.nlm.nih.gov/32157174/ 4. French data on adverse prognostic impact of del(1p32):https://pubmed.ncbi.nlm.nih.gov/36375118/ 5. S1211 study: The first high-risk enrichment RCT in myeloma (VRD vs Elo-VRD):https://pubmed.ncbi.nlm.nih.gov/33357482/ 6. Outcome of “double-hit” patients in MASTER and Dara-VRD arm of GRIFFIN trial:https://ashpublications.org/blood/article/140/Supplement%201/10144/488521 7. Impact of Auto-Transplant on decreasing MRD burden in high-risk myeloma (including double-hits):https://pubmed.ncbi.nlm.nih.gov/35731911/8. Preliminary results from GMMG-CONCEPT trial in high-risk myeloma:https://pubmed.ncbi.nlm.nih.gov/34732857/

Taking a break from finance topics this week, we're going over some of the finer details about Vintage Rotisserie Draft, ahead of the next St. Lotus event. If you don't know what VRD is, please give this a listen and if you're like to know more, join the community, and do some drafting online, head on over to https://stlotus.org/ for all that information. https://stlotus.org/build/index.html#/ https://www.twitch.tv/stlotusmtg https://articles.starcitygames.com/articles/ideas-unbound-vintage-rotisserie-draft-extravaganza/

Ständiga rekryteringsluckor. Olösliga schemapussel. Chefer och medarbetare går på knäna.  Många branscher är så hårt pressade av kompetensbrist att verksamheter har svårt att leverera. Men måste det vara så här? Gör vi kanske något fel? Letar vi kompetens på fel sätt? På fel ställen? Är vi för stressade och (omedvetet) fördomsfulla för att ha möjlighet att se kompetens och potential på nya sätt? För fega och fantasilösa för att våga prova nya vägar? Chefakademins vd Cissi Elwin tar hjälp av ett dream team för att hitta svar och lösningar: Region Stockholms hr-direktör Ulrika Sundquist, Shervin Razani, vd för Jurek Rekrytering & Bemanning, entreprenör och en av drakarna i SVT:s Draknästet och Paula Björnstjerna, Director of Nordics Linkedin Talent Solutions. Här får du koll på rekryteringsläget i Sverige just nu, hoppfulla exempel och råd om hur ni hittar vägar ut ur rekryteringsmörkret. Se samtalet som video här

On today's episode, Wes and David discuss why the VRD is required in a wind turbine environment and what exactly does it accomplish.

Muitos pacientes oncológicos têm dificuldade para entender termos médicos, como: remissão, recidiva, doença refratária, etc. Além de siglas do tratamento, como: VTD, VRD, KRD, MDT, entre outros. Por isso, neste episódio, entrevistamos a Dra. Danielle Leão, hematologista e pesquisadora clínica da BP - A Beneficência Portuguesa de São Paulo, para explicar tudo sobre os termos e tratamentos do mieloma múltiplo. Escute agora! Hosts: Bárbara Fernandes e André Torres Convidada: Dra. Danielle Leão   Site: https://www.abrale.org.br/   Instagram: www.instagram.com/abraleoficial/   Youtube: www.youtube.com/AbraleSP   Facebook: www.facebook.com/abrale   Twitter: https://twitter.com/abraleoficial Tiktok: https://www.tiktok.com/@abraleoficial

The Verde Ranger District (VRD) of the Prescott National Forest (PNF) is proposing the Verde Recreation Action Plan (VRAP) to improve recreation opportunities and natural resource conditions on the VRD. VRAP is a multifaceted plan that addresses developed and dispersed camping, river access, road and trail improvements (new and decommissions), trailhead and day-use site development, and designation of dispersed recreation areas. Prescott National Forest officials are requesting public comment and input for this proposal. While comments are welcomed at any time, they will be most effective if received by January 17, 2022. Comments should be submitted electronically via https://cara.ecosystem-management.org/Public/CommentInput?project=61156. This... For the written story, read here >> https://www.signalsaz.com/articles/public-comment-requested-for-the-verde-recreation-action-plan/

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Vincent Rajkumar, Mayo Clinic, Rochester, US, discussed: Treating elderly and frail patients with MM: Cure versus disease control.In this podcast, Rajkumar discusses the current standard of treatment for elderly, frail patients (VRd−bortezomib, lenalidomide, dexamethasone) and regimens that are currently being tested across various clinical trials to improve upon this standard, such as replacement of bortezomib with carfilzomib or daratumumab, and quadruplet combinations. He then discusses if a cure is really feasible for MM, and highlights some key considerations for a true cure; when treatment is given for a finite time and the disease never returns. He concludes with his recommendations for assessing MM cure in future trials. Hosted on Acast. See acast.com/privacy for more information.

Upphandling av hyrpersonal i vården är en omdiskuterad fråga. Kostnaderna är höga och upphandlingsmarknaden har inte fungerat särskilt bra genom åren. Varför ser det ut så här och vad krävs för att marknaden ska fungera bättre? Det diskuterar vi tillsammans med tre experter på området. I samtalet deltar Stefan Petersson, verksamhetschef i Västra Götalandsregionen, Eva Domanders, ordförande i Kompetensföretagen, och Leif Nordqvist, råd på Konkurrensverket. Leif har bland annat varit projektledare för de tidigare publicerade rapporterna Hyrläkare i primärvården från 2015 och Regioners upphandlingar av vårdpersonal från 2020.

In this episode,  Shaji K. Kumar, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD, and Jesús F. San-Miguel, MD, PhD, answer audience questions from a recent Clinical Care Options live webinar on managing multiple myeloma. Topics include:Approaches for managing smoldering multiple myelomaInsights on new strategies for managing newly diagnosed multiple myelomaIncorporating newly approved agents in the frontline and early relapse settingChoosing and sequencing BCMA-targeted therapiesManaging patients with refractory multiple myelomaPresenters:Shaji K. Kumar, MDMark and Judy Mullins Professor of Hematological MalignanciesChair, Myeloma Amyloidosis Dysproteinemia GroupConsultant, Division of HematologyMayo ClinicRochester, MinnesotaThomas G. Martin, MDClinical Professor of MedicineAssociate Director, Myeloma ProgramUniversity of California, San Francisco Medical CenterSan Francisco, CaliforniaPhilippe Moreau, MDProfessor of Clinical HematologyHead, Hematology DepartmentUniversity Hospital Hôtel-DieuNantes, FranceS. Vincent Rajkumar, MDEdward W. and Betty Knight Scripps Professor of MedicineMayo ClinicRochester, MinnesotaJesús F. San-Miguel, MD, PhDDirector of Clinical and Translational MedicineUniversidad de NavarraPamplona, SpainSupported by educational grants from Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm and Oncopeptides.Link to full program, including downloadable slidesets and expert commentaries:https://bit.ly/39MWNid 

Signé ! Mon premier CDI Apprenant est dans la poche

durée : 00:01:55 - Minute de l'Emploi

durée : 00:01:46 - Minute de l'Emploi

FDA 批准治疗慢性免疫性血小板减少症的新药BMJ 术后血栓预防中，加压袜并不能提供额外的获益Nature子刊 白血病治疗性疫苗的研制阿凡波帕（avatrombopag）阿凡波帕（avatrombopag）血小板生成素受体激动剂。在上周三《消化科星期三 Episode 23》中已经给介绍了阿凡波帕用于治疗慢性肝病合并血小板减少患者的手术前用药，可以改善血小板计数、减少出血和输血。2019年6月，该药的适应症被扩展至慢性免疫性血小板减少。《随机对照研究：阿凡波帕治疗慢性免疫血小板减少症的3期临床研究》British Journal of Haematology，2018年11月 (1)这个安慰剂对照、多中心、随机、双盲的3阶段的研究，目的是评估阿凡波帕20mg qd治疗成人慢性、免疫性血小板减少症的疗效。研究纳入49位患者，入组时血小板计数

FDA 批准治疗慢性免疫性血小板减少症的新药BMJ 术后血栓预防中，加压袜并不能提供额外的获益Nature子刊 白血病治疗性疫苗的研制阿凡波帕（avatrombopag）阿凡波帕（avatrombopag）血小板生成素受体激动剂。在上周三《消化科星期三 Episode 23》中已经给介绍了阿凡波帕用于治疗慢性肝病合并血小板减少患者的手术前用药，可以改善血小板计数、减少出血和输血。2019年6月，该药的适应症被扩展至慢性免疫性血小板减少。《随机对照研究：阿凡波帕治疗慢性免疫血小板减少症的3期临床研究》British Journal of Haematology，2018年11月 (1)这个安慰剂对照、多中心、随机、双盲的3阶段的研究，目的是评估阿凡波帕20mg qd治疗成人慢性、免疫性血小板减少症的疗效。研究纳入49位患者，入组时血小板计数

durée : 00:01:18 - Minute de l'Emploi

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Shaji Kumar, Mayo Clinic, Rochester, US. We asked: Should we use carfilzomib, lenalidomide, and dexamethasone (KRd) or bortezomib, lenalidomide, and dexamethasone (VRd) for patients with newly diagnosed multiple myeloma (NDMM)? In this podcast he describes the results of the ENDURANCE (E1A11) phase III trial.Shaji Kumar discusses the results of the primary endpoints: progression-free survival, and duration of therapy, as well as the secondary endpoints: MRD-negativity, overall survival, and toxicity. He also discusses quality of life metrics, including renal and neurotoxicity-related symptoms. As this study excluded high-risk patients, Shaji Kumar briefly describes the results of another trial (S1221) that enrolled a high-risk patient population to fully answer the question. Hosted on Acast. See acast.com/privacy for more information.

During the American Society of Clinical Oncology (ASCO) 2020 Meeting, the Multiple Myeloma Hub was pleased to speak to Enrique M. Ocio, Marqués de Valdecilla University Hospital, Santander, ES. In this podcast, Enrique M. Ocio discusses the results of the phase I/II trial that evaluated quadruplet combinations in patients with transplant-ineligible multiple myeloma.Enrique M. Ocio begins by describing how first-line treatments for this population of patients have changed recently, and then provides results from a study investigating the use of isatuximab (an anti-CD8 monoclonal antibody) in combination with quadruplet regimens; bortezomib + cyclophosphamide + dexamethasone (VCd) or bortezomib + lenalidomide + dexamethasone (VRd). He provides efficacy, safety and tolerably data as well as measurable residual disease analysis, and concludes with his perspective on which treatments should be used for elderly patients. Hosted on Acast. See acast.com/privacy for more information.

Gabriella Sonego, från Skövde, berättar i sin självbiografi om sin ovanliga hjärnsjukdom, dystoni,  och den långa vägen till diagnos och behandling. Bokpendlarna har träffat henne för ett samtal om vården, sjukdomen, fördomar och hur det var att vara ovanlig i ett litet samhälle. 

Hanna har köpt en adventskalender som en present till sig själv. Simon övar på sin nya namnteckning. Dessutom: Barn som bakar. Evidensbaserad hudvård. Paret Duggars tillbaka från frysboxen. Upprörande uppgifter om Nya Karolinska. Guidad tur på ICA Maxi.  Vi tar nu några veckors paus med podden eftersom livet är stressigt. Men vi kommer tillbaka! Prenumerera så missar du inga kommande avsnitt. Kram!

We talk a lot about the business use cases of XR on this podcast, but any good business comes with a great fitness plan or exercise room. XR is no different, and VRdōjō founder Michael Eichenseer runs Alan through a few of the cardiovascular benefits to the technology. And that’s just the first six minutes! Many other topics are touched on in this episode – virtual writing spaces, remote assistance, spatial learning, his own XR makerspace, and more. Alan: Welcome to the show, Michael, how are you doing? Pretty good. How are you? Fantastic. Thank you so much for joining me on the show today. It’s going to be a really exciting one. Let’s tell everybody at home. What is your vision for virtual augmented reality? Was the best virtual reality or a AR experience is what is the best thing that you have done? And explain to the listeners why that is so. Michael: For me, it’s definitely the fitness aspect of VR. As a gamer, I definitely enjoy the fact that I can play a game, not be sitting the entire time, and afterwards, I’ve burnt 500 calories, and feel really good about it the next day. The research coming out in XR in reducing pain and increasing motivation, to me, is fascinating. Alan: There was a lot of medical use cases coming up in pain reduction, using virtual reality for pre-surgical — and also perisurgical — where you’re wearing a headset to distract you. I know one of the things that blows my mind is, my daughter, she’s 10 and she is terrified of needles. Like, we’re talking blood-curdling screams from the nurse’s office. The next time she goes, we’re gonna use VR to try to distract her while they take blood, because it’s a stressful thing. And when somebody goes into a surgery, being able to decrease their stress; it’s hard to measure the success outcomes, but at the same time, just being able to calm them is something that I think VR does really naturally. You talked about exercising in VR. Give us some examples of some of the ways people are using VR to exercise. Michael: The boxing games are pretty popular, and I definitely have to mention Beat Saber. That’s probably the top one at the moment. Alan: Basically, you have two lightsabers in your hands, and you’ve got to swipe up and down, and left and right, with your left and right hand, and dodge out of the way of things. It is incredible. Michael: It’s dancing. Alan: Dancing and disco, and it’s so good. Michael: Yes, it’s really good. You kind of lose track of time. I think that’s why it’s good that it’s based on music; the song ends and you’re like, “oh, back to reality a little bit.”. Alan: Yeah, there’s a guy who was playing, he lost 45 pounds playing Beat Saber. Michael: Yes. I’ve actually met a 68-year-old retiree who logs into VR every morning at 5:00 a.m., just to warm up for the day. Alan: That’s incredible. What does he play? What does he do? Michael: Back when I met him, we were playing a game called Smash Box Arena. It’s a multiplayer game, kind of dodgeball. It’s defunct now, but there’s a lot of other games like that. I think Rec Room is probably the number one out there, where you can hop in — it’s a free game — and it’s cross-platform and you see people in there at all times of the day. Alan: I’ve played paintball in there. I

We talk a lot about the business use cases of XR on this podcast, but any good business comes with a great fitness plan or exercise room. XR is no different, and VRdōjō founder Michael Eichenseer runs Alan through a few of the cardiovascular benefits to the technology. And that’s just the first six minutes! Many other topics are touched on in this episode – virtual writing spaces, remote assistance, spatial learning, his own XR makerspace, and more. Alan: Welcome to the show, Michael, how are you doing? Pretty good. How are you? Fantastic. Thank you so much for joining me on the show today. It’s going to be a really exciting one. Let’s tell everybody at home. What is your vision for virtual augmented reality? Was the best virtual reality or a AR experience is what is the best thing that you have done? And explain to the listeners why that is so. Michael: For me, it’s definitely the fitness aspect of VR. As a gamer, I definitely enjoy the fact that I can play a game, not be sitting the entire time, and afterwards, I’ve burnt 500 calories, and feel really good about it the next day. The research coming out in XR in reducing pain and increasing motivation, to me, is fascinating. Alan: There was a lot of medical use cases coming up in pain reduction, using virtual reality for pre-surgical — and also perisurgical — where you’re wearing a headset to distract you. I know one of the things that blows my mind is, my daughter, she’s 10 and she is terrified of needles. Like, we’re talking blood-curdling screams from the nurse’s office. The next time she goes, we’re gonna use VR to try to distract her while they take blood, because it’s a stressful thing. And when somebody goes into a surgery, being able to decrease their stress; it’s hard to measure the success outcomes, but at the same time, just being able to calm them is something that I think VR does really naturally. You talked about exercising in VR. Give us some examples of some of the ways people are using VR to exercise. Michael: The boxing games are pretty popular, and I definitely have to mention Beat Saber. That’s probably the top one at the moment. Alan: Basically, you have two lightsabers in your hands, and you’ve got to swipe up and down, and left and right, with your left and right hand, and dodge out of the way of things. It is incredible. Michael: It’s dancing. Alan: Dancing and disco, and it’s so good. Michael: Yes, it’s really good. You kind of lose track of time. I think that’s why it’s good that it’s based on music; the song ends and you’re like, “oh, back to reality a little bit.”. Alan: Yeah, there’s a guy who was playing, he lost 45 pounds playing Beat Saber. Michael: Yes. I’ve actually met a 68-year-old retiree who logs into VR every morning at 5:00 a.m., just to warm up for the day. Alan: That’s incredible. What does he play? What does he do? Michael: Back when I met him, we were playing a game called Smash Box Arena. It’s a multiplayer game, kind of dodgeball. It’s defunct now, but there’s a lot of other games like that. I think Rec Room is probably the number one out there, where you can hop in — it’s a free game — and it’s cross-platform and you see people in there at all times of the day. Alan: I’ve played paintball in there. I

Laidą pradėsime keletu muzikos pasaulio aktualijų. Vėliau studijoje gyvai kalbėsimės su grupės „The Schwings Band“ nariais: saksofonininku ir kompozitoriumi Remigijumi Rančiu ir pianistu Richardu Baniu, neseniai grįžusiais iš 35-ojo Birminghamo džiazo festivalio. Rubrikoje „Rūgštynės“ - linksma saksofonininkės Rusnės Mikiškaitės patirtis. Taip pat klausysimės Domenico Scarlatti kūrybos. Vrd. Gerūta Griniūtė.

Rut Bjerhagen är språklärare, medlem i Neuro och har epilepsi sedan barndomen. Med åren har hon blivit resistent mot sina nödvändiga läkemedel och vardagslivet har blivit osäkert.  Kirurgisk behandling på detta område har utvecklats starkt enligt epilepsiforskarna, med goda resultat och hög säkerhet. Problemet är bara att för få patienter remitteras till utredning för en eventuell hjärnoperation, där man kan ta bort hjärnsubstansen där epilepsianfallen uppstår. Rut är nu en av de personer som har genomgått den omfattande utredningen för att se om en kirurgisk behandling är möjlig. Under tiden har hon naturligtvis tvingats att vända och vrida på alla tankar kring risker och möjligheter som en hjärnoperation innebär. I den här första delen av intervjun med Rut berättar hon öppenhjärtligt om sina funderingar inför operationen som kanske blir av och hon vill ge andra människor hopp i framtiden. Detta är en podcast av Håkan Sjunnesson NeuroMedia för Neuropodden. För medlemskap i förbundet Neuro, som samlar närstående och patienter med olika neurologiska diagnoser (som till exempel ms, Parkinson, mg, polyneuropati, als, ryggmärgsskador och stroke) gå in på www.neuro.se. Här kan du också stödja den neurologiska forskningen via Neurofonden. 

Patientriksdagen är ett initiativ från fem patientorganisationer; Neuro, Riksförbundet HjärtLung, Astma- och allergiförbundet, Huvudvärksförbundet och Blodcancerförbundet, i samarbete med Novartis. Syftet var att sätta patientens röst i centrum och skapa en arena där angelägna frågor kan diskuteras utifrån ett patientperspektiv. Lise Lidbäck medverkade som både gruppsamtalsledare och i panelsamtal. I denna podcast medverkar bland andra Lise Lidbäck Neuro, Emma Spaak läkare SKL, Göran Hägglund moderator, Inger Roos Hjärt-Lung, Acko Ankarberg ordförande Socialutskottet, Jonas Andersson ordförande Hälso- sjukvårdsstyrelsen VGR och Ann Johansson, vice förbundsordförande Vårdförbundet. En podcast av Håkan Sjunnesson NeuroMedia för Neuropodden. För medlemskap i Neuro eller bidra till neurologisk forskning eller Neuro: www.neuro.se   Det här var den första patientriksdagen som hade temat patientlagen, om patienternas ställning i hälso- och sjukvården som länge har varit föremål för diskussion. En rad initiativ har tagits för att förbättra och förtydliga vad patienten har rätt att förvänta sig, bland annat en ny patientlag. Patientlagen är omdiskuterad och det har ifrågasatts huruvida den verkligen fyller sitt syfte: att stärka och tydliggöra patientens ställning. Under denna pateintriksdag, som hölls på kongresscentret Norra Latin i centrala Stockholm den 7 maj 2019, var några av patientlagens delar i fokus. Det handlade om 5 kap. Delaktighet, 6 kap. Fast vårdkontakt och individuell planering och 11 kap. Synpunkter, klagomål och patientsäkerhet. Det senaste var Neuroordföranden Lise Lidbäck moderator.     Här är de delar i Patientlagen som diskuterades: Kapitel 5 – delaktighet Patientlagens femte kapitel anger att hälso- och sjukvården så långt som möjligt ska utformas och genomföras i samråd med patienten (1 §). Vidare ska en patients medverkan i hälso- och sjukvården utgå från patientens önskemål och individuella förutsättningar, genom att hen själv utför vissa vård- eller behandlingsåtgärder (2 §). Patientens närstående ska också kunna medverka vid utformningen och genomförandet av vården, om det är lämpligt och om bestämmelser om sekretess eller tystnadsplikt inte hindrar detta (3 §). Kapitel 6 - fast vårdkontakt och individuell planering Patientlagens sjätte kapitel anger att patientens behov av trygghet, kontinuitet och säkerhet ska tillgodoses. Samt att olika insatser för patienten ska samordnas på ett ändamålsenligt sätt (1 §). En fast vårdkontakt ska utses för patienten om hen begär det, eller om det är nödvändigt för att tillgodose patientens behov av trygghet, kontinuitet, samordning och säkerhet (2 §). Vidare framkommer att patienter ska få möjlighet att välja en fast läkarkontakt inom primärvården (3 §). Kapitel 11 - synpunkter, klagomål och patientsäkerhet Patientlagens elfte kapitel – Synpunkter, klagomål och patientsäkerhet, innehåller bland annat bestämmelser om Patientnämndernas samt Inspektionen för vård och omsorgs uppdrag och skyldigheter (1 och 3 §). Att vårdgivare snaraste ska besvara klagomål från patienter och deras närstående (3 §). Vidare framkommer vårdgivarnas skyldigheter att ge särskild information till patienter som har drabbats av en vårdskada (3 §). Patienten och dennes närstående ska också få möjlighet att delta i vårdgivarens patientsäkerhetsarbete (4 §).

Att det finns en lag för VAB, alltså vård av sjukt barn känns ju självklart, i alla fall för oss här i Sverige. Att inte kunna ha möjligheten att vara hemma och ta hand om sitt sjuka barn hade ju varit fullkomligt absurt. Tänk er om man hade behövt lämna sitt sjuka barn, som man älskar mest av allt i världen till sitt eget öde för att du behövde gå och jobba. tanken är galen! Varför är det då sån skillnad då det kommer till husdjur? Varför är tanken att få “vabba” sitt husdjur för många människor lika absurd som att inte få vabba sitt barn? Tillsammans med Kris-Kicki pratar vi i veckans avsnitt om Vah - vård av husdjur, om egna erfarenheter och om det skulle vara möjligt att genomföra. Glöm inte prenumerera på Kattsnackspodden!

150 personer inom vården, i det nationella nätverket för diagnosen als, amyotrofisk lateralskleros, möttes i Lund nyligen. Neuropodden var också på plats och fick möjlighet att göra flera intervjuer. Det här webbradioreportaget gör ett försök att spegla det svåra arbetet som personal i olika nyckelroller utför. Dels för den som är sjuk i als och dels för närstående och anhöriga.  Detta podcastreportage beskriver hur dietister, sexologer, läkare och sjuksköterskor bland alla dessa olika yrkesroller ser på vården i multidisiplinära team. Medverkar gör bland andra Ingela Nygren neurologläkare vid Akademiska sjukhuset Uppsala, Anneli Rosan sjuksköterska als-team Göteborg, Gert Staaf neurolog och Teamledare vid SUS och Erika Stenberg forskningssjuksköterska vid Norrlands universitetssjukhus i Umeå. Neuropodden var också på plats när Neuro (Neuroförbundet) ordnade en medlemskväll om just diagnosen als i Lund, då intresserade fick lyssna på den neurologiska forskningen och prata med ledande als-specialistneurologer. I slutet av detta podcastavsnitt, får du några röster av de als-patienter som var på plats. En podcast av Håkan Sjunnesson NeuroMedia för Neuropodden. För mer information om als och neurologisk forskning och för att bli medlem i Neuro och ge ett ekonomiskt bidrag: www.neuro.se  

Sveriges befolkning blir allt äldre och kräver därmed mer vård. Samtidigt ser vi också att kostnaderna skenar i vården och att vårdkostnaderna utgör en allt större del av många länders BNP. Hur ska vi organisera hälso- och sjukvården för att möta framtidens behov? Dessa frågor tar vi oss an i den här månadens avsnitt av Centigopodden. Med oss i studion har vi Barbro Fridén som är läkare och gynekolog. Barbro har erfarenhet av att leda såväl små som stora sjukvårdsorganisationer, i både Sverige och i utlandet. Senast var hon chef för Sahlgrenska Universitetssjukhuset i Göteborg.

I det här avsnittet frågar lyssnarna ut beteendevetaren och djurtränaren Eva Bertilsson. Några frågor som hon besvarar är följande: ⚫ Hur tränar man frivillig hantering i duschen?  ⚫ Hur gör man för att börja träna frivillig hantering när hantering redan blivit något obehagligt och jobbigt? ⚫ Hur tränar man hunden att gilla tandborstningen? ⚫ Hur man kommer åt tänderna längst bak? ⚫ Hur gör jag för att underlätta öronrengörning?   #VårBästaVän är och ska vara gratis att lyssna på, just nu planerar jag säsong 8 och undrar om du kan tänka dig att stötta Nordens största folkbildande podd om hundar? Du stöttar podden genom att ge ett valfritt belopp via bankgiro (5065-5042 och märk med SÄSONG 8) eller Swisha och märk meddelandet med SÄSONG 8 till nr:

Våra hundar får stå ut med mycket! Päls ska vårdas, dom blir fasthållna av främmande personer på märkliga platser som ska undersöka dom, klor ska klippas och tänder borstas. Men tänk om hunden själv fick styra över kloklippning och tandborstning? Tänk om allt det här kunde vara en kul aktivering istället för en besvärlig stund? Tänk om man kunde göra ett nödvändigt ont till ett samarbete? Jag samtalar med beteendevetaren och djurtränaren Eva Bertilsson, som föreläser om hundträning och hundars beteende och lärande och hon undervisar även blivande hundinstruktörer och instruktörslärare, främst inom inlärningsteori, allmänlydnad och agility. Vi pratar om: ⚫ Hunden har kontrollen och hunden har rätten att säga nej ⚫ Hundens kroppspråk och signaler ⚫ Inlärd hjälplöshet ⚫ Stressminimering ⚫ Snälla händer  ⚫ Bestraffning, disciplin och dominans ⚫ Snabba lösningar som skapar nya problem ⚫ Kloklippning, pälsvård, tandborstning och öronrengöring #VårBästaVän är och ska vara gratis att lyssna på, just nu planerar jag säsong 8 och undrar om du kan tänka dig att stötta Nordens största folkbildande podd om hundar? Du stöttar podden genom att ge ett valfritt belopp via bankgiro (5065-5042 och märk med SÄSONG 8) eller Swisha och märk meddelandet med SÄSONG 8 till nr:

Neuropodden/Neurologipodden: Det har i flera år talats om att vi i Sverige måste få till en mycket mer värdebaserad och personcentrerad vård. I praktiken är sjukvården svår att reformera, och mycket blir inte som det var tänkt. Men nu kommer förändringen. Den drivs av krafter utifrån, av ny teknik, av patienters förväntningar och av innovatörer som utmanar traditionella hierarkier.  Därför arrangerade Dagens Industri Health Care denna seminariedag om hur patienterna ska bli delaktiga, vården ska bli jämlik och hålla hög kvalitet och det ska ske samtidigt. Neuroförbundets, Neuros ordförande Lise Lidbäck medverkade som patientrepresentant och berättade om sin egen starka patientberättelse. Om att få vården att fungera när man lever med en neurologisk diagnos och blir svårt skadad i en bilolycka. Det skakade om konferensdeltagarna. I denna podcast medverkar också Anders Henriksson 1:e vice ordförande SKL om hur sjukvården ska omstruktureras, Mårten Blix vid Institutet för Näringslivsforskning (IFN) föreläste om digitala sjukvårdskontakter, om Nätdoktorn – fripassagerare eller frälsare? Anna Krohwinkel, forskningschef vid Stiftelsen Leading Health Care gav sin och tankesmedjans syn på spetspatienter som innovatörer. Vidare intervjuas Yvonne Haglund Åkerlind, vd Danderyds sjukhus, Kristina Niemi kanslichef på Neuro och Maja Flodin moderator på Dagens Industri Health Care. Detta är ett podcast-reportage producerat för Neuropodden av Håkan Sjunnesson NeuroMedia 2018. För mer info om Neuro (Neuroförbundet), bli medlem och/eller bidra till den neurologiska forskningen och vården: www.neuro.se  

Ett dussin personer rör sig rytmiskt och vågformigt över golvet på Folkuniversitetets och Balettakademiens Neurodans. Den gemensamma nämnaren är att alla i danstruppen har neurologiska symtom, med olika grad av neuropatisk smärta och olika muskler som inte längre riktigt lyder viljan. Några är rullstolsanvändare och i vissa övningar sitter alla ner. I nästa övning rör sig alla framåt som en danstrupp och av deltagarnas utstrålning att döma är detta en riktig energigivare.   Solen lyser in genom den vackra danssalens höga fönster och på det stora solvarma trägolvet rör sig människor koncentrerat och graciöst. Nyss var det en rytmisk poplåt men nu strömmar klassisk musik ur högtalarna här på neurodansen. Det är både stående och sittande människor, med olika neurologiska diagnoser, som här kan dansa utifrån sin egen förmåga. Allt under ledning av danspedagogerna Åsa N. Åström och Jennifer Johannesson från Balettakademien, som turas om att instruera gruppen. Dansövningarna varierar mycket och det byggs kroppspyramider, man skickar kroppsbudskap till varandra och rör sig över salsgolvet i formationer. Danspedagogernas filosofi är att dansen utvecklar hjärnan och kroppens motorik, samtidigt som personerna bygger självförtroende och ökar sin livsglädje. En perfekt modell för personer med olika neurologiska diagnoser, där muskler inte längre fungerar som man var van vid. En podcast av Håkan Sjunnesson / NeuroMedia för Neuropodden Bli medlem, ge en gåva och följ det arbete Neuro (Neuroförbundet) gör för att neurologisk rehabilitering och forskning ska vara en självklarhet.  www.neuro.se

Inför Valet 2018 har ordförande Lise Lidbäck tillsammans med övriga förtroendevalda och kanslipersonalen i Neuro (Neuroförbundet), jobbat intensivt med att försöka föra fram angelägna vårdfrågor. Det handlar framför allt om rehabilitering och att snabbt få rätt diagnos ställd. Mycket viktigt för den som har konstiga neurologiska symtom och för att kunna påbörja en behandling. I den här Neuropodden intervjuas Neuros ordförande Lidbäck om Neuros krav på politiken, när det handlar om neurosjukvården. Det gäller framför allt att alla som behöver rehabilitering vid en neurologisk skada eller sjukdom ska få det. Behovet är stort och tyvärr skiljer sig möjligheterna mycket i landet. Värst är det från Uppsala och norrut, där många medlemmar är besvikna över den bristfälliga och i flera fall i princip obefintliga möjligheten till sammanhållen intensiv rehabilitering under individuell ledning. - Detta är oacceptabelt eftersom alla människor med neurologiska diagnoser mår bättre med rätt sorts individuell rehabilitering. En förutsättning för ett så bra liv som möjligt, säger Lise Lidbäck. Neuro kräver också att en parlamentarisk utredning ställer diagnos på den neurologiska rehabiliteringen i Sverige och kommer med åtgärdspaket för att den ska bli acceptabel. En podcast av Håkan Sjunnesson / NeuroMedia för Neuropodden #funkpol #neuro #neuromedia #val #valet2018 #vård #riksdagen #sjukvård #rehabilitering #rehab #godochnäravård #ms #stroke #als #dm_agenda

Mer välvilja än konkreta förslag när det gäller vård och omsorg. Så kan svaren på SPF Seniorernas valenkät till riksdagspartierna sammanfattas. - Alla svaren andas att dom vill göra något åt det här och det de säger låter vettigt. Men hur det här ska gå till saknas nästan alltid. Det säger Gösta Bucht, som är sakkunnig inom SPF Seniorerna när det gäller frågor inom vård och omsorg. - Vallöften i all ära, men om de inte är konkreta går de inte att följa opp och man vet inte vad som händer. Man borde bli bättre där och konkret tala om vad man vill, säger han. I det här avsnittet av Seniorpodden diskuteras svaren inom vård och omsorg i valenkäten.

Under Almedalsveckan 2018 arrangerade Dagens Medicin ett maktmingel för de personer som i år har listats som de 100 mest inflytelserika personerna i VårdSverige enligt Dagens Medicins bedömning. Den stora nyheten i år är att hela sju representanter för patientorganisationer har kvalat in och två av dem är medlemmar i Neuro; Lise Lidbäck och Sara Riggare. Listan toppas av socialminister Annika Strandhäll, som är intervjuad i denna podcast, liksom bland andra Anders Blanck LIF, Lotta Håkansson reumatikerförbundet och Inger Roos Hjärt-Lung. En podcast för Neuropodden av Håkan Sjunnesson / NeuroMedia www.neuro.se #neuro #almedalen #almedalen2018 #neuromedia #skl #lif #dm_agenda #funkpol #genterapi #dmagenda Se hela maktlistan 2018: https://www.dagensmedicin.se/artiklar/2018/06/27/skifte-i-toppen-pa-maktlistan-2018/

Genom en så kallad trombektomi kan en stor blodpropp dras ur ett blodkärl med en tunn liten korg som förs in i blodådran och på så sätt förhindra neurologiska skador på hjärnan. En mycket effektiv behandling som kräver att patienten sjukhusbehandlas inom några få timmar. Neuros ordförande medverkade i ett kreativt samtal om framtidens akuta strokevård under Almedalsveckan 2018. Hör Neuropoddens reportage!   I dag är det kraftig underbehandling och ojämlik tillgång till mekanisk trombektomi vid stroke, trots evidens och Socialstyrelsens nya nationella riktlinjer. Och kring hur kan den vårdformen ska bli mer tillgänglig och användbar i framtiden, hölls ett kreativt rundabordssamtal under Almedalsveckan 2018. En av de medverkande var Neuros ordförande Lise Lidbäck och lyssna på hennes och några av de andras spännande tankar om akut strokevård i denna podcast. Medverkande i inslaget är Lise Lidbäck förbundsordf Neuro, Anders Henriksson 1:e v ordf SKL, Jesper Petersson ordf programråd nervsystemets sjukdomar, Per Arnell Ambulanshelikopterverksamhen VGR, Lars Rosengren ordf. nat. arbetsgrupp stroke. #dm_agenda #neuro #almedalen #almedalen2018 #neuromedia #stroke #funkpol #lif #vård En podcast för Neuropodden av Håkan Sjunnesson / NeuroMedia 2018

Den kritiskkonstruktiva rapporten "Vård i världsklass" presenterades officiellt under Almedalsveckan 2018 och den är framtagen av Neuro i samverkan med fem andra opinionsbildande aktörer inom patientföreningsfären; Riksförbundet HjärtLung, Reumatikerförbundet, Astma och AllergiFörbundet, Diabetesorganisationen i Sverige och Storstockholms Diabetesförening. -Två års givande framtidsarbete, säger Lise Lidbäck.  En podcast av Håkan Sjunnesson / NeuroPodden och NeuroMedia #almedalen2018 #neuro #rehab #funkpol #Almedalen #neuromedia Gruppen av organisationer som tagit fram rapporten menar att den svenska sjukvården ofta beskrivs som ett internationellt föredöme av politiker inom hälso- och sjukvården. Oavsett politisk färg. Ett vanligt argument är att den svenska vården levererar vård i världsklass till måttliga kostnader. Denna rapport tecknar en annan bild av den svenska sjukvården. Det är dags att modifiera bilden av den svenska sjukvården, enligt rapportskribenterna. Vården fortfarande otillgänglig Lise Lidbäck är nöjd med den rapport som Neuro (Neuroförbundet) varit med om att ta fram eftersom det finns mycket kvar att göra för personer med troligtvis livslånga neurologiska diagnoser. Att vården ska vara rättvis och tillgänglig för alla, oavsett var man bor i Sverige:- I stort konstaterar rapporten att Sverige ligger högt i jämförelse med andra länder när det handlar om medicinska behandlingsresultat. Inte oväntat ligger vi däremot betydligt sämre till när det gäller sjukvårdens förmåga att skapa en tillgänglig och patientcentrerad vård, berättar Lise Lidbäck, förbundsordförande för Neuro (Neuroförbundet).

Med en placering som nummer 33 på Dagens Medicins åtråvärda topp 100 sjukvårdsmaktlista, ser Neuros ordförande Lise Lidbäck mycket fram emot att medverka på en rad seminarier om neurosjukvård på Almedalsveckan 2018. Hon vill ge Neuros medlemmar en starkare röst och att det ska bli fokus för den personcentrerade neurosjukvården i framtiden.  En podcast av Håkan Sjunnesson / NeuroMedia #Almedalen #almedalen2018 #neuropodden #neuro #vård

Den 28 mars 2018 presenterade Socialstyrelsen de reviderade nationella riktlinjerna för strokevården. Och en av de få patientorganisationernas representanter som deltagit i prioriteringsarbetet av vårdinsatser är Roger Lindahl i patientorganisationen Neuro (Neuroförbundet). I den här Neuropoddintervjun får du veta det viktigaste innehållet i riktlinjerna ur ett patientperspektiv. Roger ger dig också argument för vad du kan begära av den vårdpersonal du möter. En snabbt insatt intensiv och också långvarig rehabilitering är avgörande för att återupprätta förlorade kroppsfunktioner efter en stroke, en hjärnblödning eller en blodpropp i hjärnan. Att kunna upprätthålla en god munhygien och sväljfunktion är några av de nya prioriteringar som förts in i de nationella riktlinjerna för vården av strokepatienter. Liksom att behandla afasi och depressioner med högre kvalitet. Snabba sjukhustransporter har en hög prioritet liksom att med hjälp av så kallad trombektomi plocka ut stora blodproppar, innan de orsakar skada i hjärnan. Den här Neuropodden är producerad av Håkan Sjunnesson för NeuroMedia. Läs mer om strokevården på www.neuro.se   ---------------------- Så ser du om någon har drabbats av stroke För att rätt vård ska kunna ges, måste sjukvården alarmeras så fort som möjligt när någon drabbas av stroke. Det kan vi alla gemensamt hjälpa till att vara förberedda för att göra, med hjälp av kunskaper om AKUT-testet. Ansikte Den del av hjärnan som styr motoriken i ansiktet är ofta påverkat av en stroke. Genom att be en person le går det att avslöja om båda sidorna hänger med. Om ena sidan är slapp även när personen ler, tyder det på stroke. Hög tid att ringa SOS Alarm – 112. Kroppsdel Genom att be en person att sträcka båda armarna rakt fram kan också den för stroke så vanliga sidoförlamningen lätt upptäckas. Om ena armen faller är risken för stroke uppenbar. Uttal Talsvårigheter är mycket vanliga vid stroke. Be personen som är drabbad av ett anfall att upprepa en enkel mening. Om personen ifråga misslyckas, handlar tillståndet om ett pågående stroke- alternativt TIA-anfall. Tid Tiden i AKUT-testet handlar om att agera direkt. Varje sekund räknas om en person drabbas av stroke. Tveka inte att alarmera och ringa efter ambulans.

Hur skapar man en ”sömlös” personcentrerad vård, som hänger ihop för varje patient och som inte orsakar sömnlöshet för oroliga människor? Det funderar regeringens särskilda utredare Anna Nergårdh intensivt på.  Hör ett spännande resonemang om vårdköer, läkare som inte lyssnar och remitterar vidare och det virala Metoo-upproret. Anna är läkare i grunden och har fått ansvaret att leda ett omfattande utredningsarbete, som ska leda fram till en plan för hur sjukvården ska fungera för oss med särskilt fokus på första linjens sjukvård, nära oss medborgare, den så kallade primärvården. Men då måste vården omstruktureras så att resurserna satsas rätt. Den här intervjun för Neuropodden producerades av Håkan Sjunnesson/ NeuroMedia.  För mer information om neurologisk forskning, fakta om neurologiska diagnoser och Neuros (Neuroförbundets) verksamhet: www.neuro.se  Hälsa, vetenskap, medicin, forskning 

I vilket etnologen Jens Lindberg berättar om hur sjukvården bemöter manliga våldtäktsoffer.

Visste ni att det finns en djurambulans som täcker hela Stockholms län dygnet runt året om? Inte alla djurägare har egen bil eller körkort och det är få taxibolag som tar djur i sina bilar och därför finns Djurambulansen Stockholm! Två ideella hjältar, Carina och Monica, berättar om hur de kör akut djurtransport till veterinärkliniker eller djursjukhuser i Stockholm! Hur är det att inte kunna komma fram i tid i den stökiga Stockholmstrafiken? Vilka är de vanligaste orsakerna till att de måste rycka ut? Hur är det att ta hand om djuren och ägarna samtidigt?  Flera avsnitt kommer att publiceras från Stockholm Hundmässa de kommande veckorna framöver. Som vanligt släpps nya avsnitt varje måndag och torsdag kl 10:00!   

Joel berättar om sitt jobb som psykolog inom öppenvården. Vi får även veta vad som skiljer psykologyrket från andra liknande yrken inom samma sfär. Och vad betyder egentligen KBT?